Updates in Atopic Dermatitis Management: Clinical Insights from the SDPA Summer Conference

Atopic dermatitis treatment continues to evolve as clinicians shift from generalized immunosuppression toward targeted biologic therapies and JAK inhibitors. During the Society of Dermatology Physician Assistants (SDPA) Summer Dermatology Conference, experts emphasized that successful management now requires a personalized approach that balances long-term safety with rapid symptom relief, particularly for patients with moderate-to-severe disease.

Why Targeted Therapies Are Changing Patient Outcomes

The standard of care for atopic dermatitis has historically relied on topical corticosteroids and broad-spectrum systemic agents. According to the American Academy of Dermatology (AAD), the introduction of biologic agents like dupilumab and tralokinumab, along with oral Janus kinase (JAK) inhibitors such as upadacitinib and abrocitinib, has significantly improved patient outcomes. These medications target specific inflammatory pathways, such as IL-4 and IL-13, which drive the skin barrier dysfunction and intense pruritus characteristic of the condition.

Clinicians are moving toward these advanced options earlier in the treatment algorithm. Unlike traditional therapies that often come with significant side-effect profiles, targeted agents allow for sustained disease control without the systemic risks associated with chronic corticosteroid use.

How Clinicians Select Between Biologics and JAK Inhibitors

Choosing the right therapy requires a careful assessment of a patient’s medical history and treatment goals. Research published in the Journal of the American Academy of Dermatology highlights that while biologics are often favored for their safety profile and long-term efficacy, JAK inhibitors provide a faster onset of action for patients suffering from acute, severe flare-ups.

• Biologics: Best suited for patients requiring long-term, continuous management with a low risk of serious adverse events.
• JAK Inhibitors: Preferred for patients who need rapid relief from debilitating itch or those who have failed to respond to injectable biologics.

The choice between these classes often depends on a patient’s preference regarding the route of administration—injections versus daily oral tablets—and the necessity for routine laboratory monitoring, which is more common with certain JAK inhibitors.

Addressing Common Barriers to Effective Treatment

Even with new therapies, access and insurance authorization remain significant obstacles. According to the National Eczema Association, patients often face “step therapy” protocols that require the trial of less effective or cheaper medications before insurance companies approve high-cost biologics. This can delay the path to remission and increase the burden on the patient.

Physician assistants and dermatologists are increasingly using standardized assessment tools, such as the Eczema Area and Severity Index (EASI) and the Investigator’s Global Assessment (IGA), to document disease severity clearly. Providing objective data in clinical notes is essential for securing prior authorizations and ensuring patients receive evidence-based care in a timely manner.

Future Directions in Atopic Dermatitis Care

The landscape of dermatology is moving toward precision medicine. Ongoing clinical trials are investigating additional pathways, including OX40 and TSLP inhibitors, which may offer further options for patients who do not achieve complete clearance with current standards. By focusing on the specific inflammatory profile of each patient, clinicians aim to achieve “clear or almost clear” skin consistently, rather than simply managing episodic flares.

Key Takeaways for Practitioners

• Prioritize Skin Barrier Repair: Regardless of systemic therapy, topical emollients remain the foundation of care to prevent transepidermal water loss.
• Monitor for Comorbidities: Atopic dermatitis is frequently associated with asthma, allergic rhinitis, and food allergies; a multidisciplinary approach is often required.
• Document Severity: Using validated scales like the EASI score is critical for tracking patient progress and securing insurance coverage for advanced therapies.

As research continues, the focus remains on reducing the long-term morbidity of atopic dermatitis. By integrating these new therapeutic classes into practice, providers can provide more effective, individualized care for patients who previously had few options beyond topical steroids.